Physician profile
Joel Jacowitz
NPI 1922009760
$1,492.71
in general payments reported to CMS, 2019-2025
19 companies · $644 in 2025
The $644 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.02 · 2021: $87.26 · 2022: $245 · 2023: $232 · 2024: $219 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,095.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $318.33 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $275.47 | 2022-2025 | Repatha, Repatha |
| Medtronic, INC. | $157.55 | 2025 | Abre |
| Abbott Laboratories | $154.85 | 2025 | Cardiomems |
| Irhythm Technologies, INC. | $102.44 | 2022-2023 | Zio Xt Patch |
| Novartis Pharmaceuticals Corporation | $88.65 | 2021-2025 | |
| Pfizer INC. | $67.45 | 2024-2025 | |
| Bridgebio Pharma, INC. | $53.46 | 2025 | Attruby |
| Corcept Therapeutics | $51.91 | 2025 | Korlym |
| Heartflow, INC. | $48.55 | 2024 | |
| Janssen Biotech, INC. | $29.20 | 2019 | |
| Merck Sharp & Dohme LLC | $28.36 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.78 | 2025 | |
| Abiomed | $19.91 | 2019 | |
| Boston Scientific Corporation | $15.91 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.40 | 2023 | |
| Amarin Pharma, INC. | $14.62 | 2021 | |
| Octapharma USA, INC. | $13.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Jacowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.